News
Race Oncology (ASX: RAC) is an ASX-listed clinical stage, global biotechnology company with a dedicated mission to be at the heart of cancer care. Race’s lead asset, bisantrene, is a small molecule anthracene chemotherapeutic. Bisantrene has a unique and rich clinical history with demonstrated therapeutic benefits in both adult and paediatric patients, as well characterised safety profile, and compelling clinical data demonstrating an anti-cancer effect and a lack of cardiotoxicity.
Race is developing bisantrene to address the high unmet need of patients across multiple oncology indications, with an initial focus on metastatic breast cancer (lead indication) and acute myeloid leukaemia (AML), exploring anti-cancer plus cardio-protection in synergy with known standards of care.
As part of its clinical program, Race is also investigating the impact bisantrene and new molecules have on the m6A RNA pathway, following independent research describing bisantrene as the most potent inhibitor of FTO (Fat mass and obesity-associated protein). Dysregulation of RNA (over expression of FTO) has been shown to be a driver of a diverse range of cancers.
Race Oncology is in collaboration with City of Hope, MD Anderson, Sheba City of Health and UNC School of Medicine, and is actively exploring partnerships, licence agreements or a commercial merger and acquisition to accelerate access to bisantrene for patients with cancer across the world. Learn more at www.raceoncology.com
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
Check Up: Only two healthcare IPOs from 2021 are gaining ground, could the rest be buying opportunities?
Health & Biotech
Another breakthrough for Zantrene as Race Oncology significantly expands its addressable market
News
Closing Bell: Volatile gains on Tuesday as ResApp retires, Metals Grove adds 50% in pithy Pilbara pegmatite pop
Health & Biotech
ASX Health Stocks: Race to develop RNA-based therapies is well and truly on, as these two biotechs add new programs
Investor Guides
Investor Guide: Health & Biotech FY2023
Health & Biotech
Race Oncology’s breakthrough in Zantrene offers huge market opportunity in chemotherapy
Health & Biotech
ASX Health Stocks: Cann’s Mildura cannabis facility gets GMP licence, unlocking export markets
Health & Biotech
Check Up: Samsung and Big Pharma give big thumbs up to biotech sector
Health & Biotech
ASX Health Stocks: Race Oncology says Zantrene improves melanoma immune therapy
News
Rise and Shine: What you need to know before the ASX opens
News
Closing Bell: Weak leads, weak banks, a one month low and not enough energy to go round
News
ASX Small Cap Lunch Wrap: Who else is groping about in the dark today?
Health & Biotech
ASX Health Stocks: Race Oncology is set to expand its clinical trial to Spain and Italy
Health & Biotech
ASX Health Stocks: Race Oncology blows past dosing stage of Phase 1, targets Phase 2
Health & Biotech
ASX Health Stocks: Race and Rhythm make their moves to advance Australian share
Health & Biotech
4D Medical CEO hails launch of world’s first dedicated lung scanner, stock price jumps 30pc
Health & Biotech